InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Hrynkow Sharon Hemond, Directeur Scientifique. Officer active across 2 companies, notably Cyclo Therapeutics, Inc.. Aggregated, 2 filings have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €10k. Activity tracked since 2 December 2021. The latest transaction was filed on 20 December 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Hrynkow Sharon Hemond
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报2 总计
5,000 股@ US$1.13100.0% 占其流量Common StockSEC:0001683168-22-008580:0
标准退出：2023年3月20日 (T+90)
1,000 股@ US$4.98100.0% 占其流量Common StockSEC:0001437749-21-027716:0
标准退出：2022年3月2日 (T+90)
2 条申报中的 2 条
About Hrynkow Sharon Hemond
Hrynkow Sharon Hemond is the Chief Scientific Officer of Cyclo Therapeutics, Inc. She is responsible for leading the company's research and development initiatives. Her role involves overseeing scientific projects and ensuring that research objectives are met. With extensive expertise in her field, she plays a key role in the innovation of the company's products.
